Skip to main content

Table 1 Baseline characteristics of patients treated with blood-derived DC vaccinations

From: Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Patienta Age
(years)
Gleason score Prior treatments Time start ADT to CRPC
(mo)
Baseline PSA (ug/l)b Baseline LDH
(U/l)b
Baseline ALP
(U/l)b
All disease sites at baselinec
mDC-01 60 4 + 5 GOS, BIC 55.4 5.8 187 100 Local, LN, bone
mDC-02 67 4 + 4 PLND, GOS 20.7 4.6 152 80 Local, LN
mDC-03 67 3 + 4 PRTX, GOS, BIC 93.9 10 257 61 Local, LN
mDC-04 60 4 + 3 RP, SRTX, PLND, GOS, BIC 21.5 39 147 113 LN, bone
mDC-05 78 3 + 4 RP, SRTX, PLND, SO, BIC 34.7 4.8 211 79 LN
mDC-06 71 4 + 5 BIC + DUT, SO 94.5 40 185 101 Local, LN, bone
mDC-07 72 5 + 5 CRT, PRTX, PLND, GOS, BIC 27.7 260 222 260 LN, bone
pDC-01 72 5 + 5 PRTX, PLND, LEU, BIC 28.5 6.3 181 98 LN
pDC-02 59 4 + 5 PRTX, GOS, BIC, NIL, DUT, ABI + P/D 83.4 3.6 222 102 Local, LN, bone
pDC-03 59 5 + 5 PLND, LEU, BIC 29.0 8.4 176 81 Local, LN, bone
pDC-04 70 3 + 4 RP, SRTX, PLND, BIC, SO 42.3 19 174 88 LN
pDC-05 65 4 + 3 RP, SRTX, LEU, BIC 41.6 2.6 169 138 LN, bone
pDC-06 79 5 + 4 GOS 85.7 5.7 164 95 Local, LN
pDC-07 82 4 + 5 GOS, BIC 91.6 17 201 53 Local, LN, bone
combiDC-01 74 3 + 4 GOS 46.1 38 168 96 Bone
combiDC-02 67 4 + 4 LEU, BIC 27.6 41 172 83 Local, bone
combiDC-03 63 5 + 4 GOS, LEU, BIC 53.9 18 233 79 Local, LN
combiDC-04 73 4 + 3 LEU, BIC, ENZ 39.3 8.7 179 73 Local, bone
combiDC-05 61 4 + 5 GOS, BIC, ENZ 40.5 3.7 205 123 Local, LN, bone
combiDC-06 73 4 + 4 PRTX, GOS, LEU, BIC, ENZ 20.4 11 131 73 LN, bone
combiDC-07 53 4 + 4 DEG, BIC, ABI + P, SO, ARN-509 29.4 120 161 83 LN, bone
  1. ABI + P: abiraterone plus prednisone; ABI + P/D: abiraterone plus prednisone + switch of prednisone to dexamethasone at PSA-progression; ADT: androgen deprivation therapy; ALP: alkaline phosphatase; ARN-509: apalutamide, ClinicalTrials.gov identifier (NCT number): NCT01946204; CRT cryotherapy, BIC bicalutamide, CRPC castration-resistant prostate cancer, DC dendritic cells, DEG degarelix, DUT dutasteride, ENZ enzalutamide, GOS goserelin, LDH lactate dehydrogenase, LEU leuprorelin, LN lymph node, mo months, NIL nilutamide, PLND pelvic lymph node dissection, PRTX primary radiotherapy, PSA prostate-specific antigen, RP radical prostatectomy, SO surgical orchidectomy, SRTX salvage radiotherapy
  2. avaccination with myeloid DC (patient mDC-01 to mDC-07), plasmacytoid DC (patient pDC-01 to pDC-07) or combined myeloid DC + plasmacytoid DC (patient combiDC-01 to combiDC-07)
  3. bmeasured prior to apheresis
  4. cattributed by experienced nuclear medicine specialists and radiologists. Detected at advanced imaging with contrast enhanced 68Ga-prostate-specific membrane antigen PET/CT scans, ferumoxtran-10-enhanced MRIs and MRI bones using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria